This trial is conducted in Japan. The aim of this clinical trial is to investigate the blood sugar lowering effect of NN5401 (insulin degludec/insulin aspart (IDegAsp)) in Japanese subjects with type 1 diabetes. Each subject will be randomised to one of the two possible treatment sequences (NN5401 followed by biphasic insulin aspart (BIAsp) 30 or biphasic insulin aspart 30 followed by NN5401).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
21
Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
Novo Nordisk Investigational Site
Tokyo, Japan
Area under the Glucose Infusion Rate curve after a single dose
Time frame: From 4-12 hours
Area under the insulin aspart concentration-time curve after a single dose
Time frame: From 0-12 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.